04.26.18
AbbVie
1Q Revenues: $7.9 billion (+21%)
1Q Earnings: $2.8 billion (+63%)
Comments: Global HUMIRA sales were $4.7 billion, up 14%. IMBRUVICA sales were $762 million, up 39%. Global HCV sales were $919 million in the quarter, up more than 100%. Synagis
sales were up 7% to $321 million. Duodopa sales were up 17% to $103 million. Kaletra sales continued to decline to $73 million, down 39% in the quarter.
1Q Revenues: $7.9 billion (+21%)
1Q Earnings: $2.8 billion (+63%)
Comments: Global HUMIRA sales were $4.7 billion, up 14%. IMBRUVICA sales were $762 million, up 39%. Global HCV sales were $919 million in the quarter, up more than 100%. Synagis
sales were up 7% to $321 million. Duodopa sales were up 17% to $103 million. Kaletra sales continued to decline to $73 million, down 39% in the quarter.